Cargando…
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
Platinum-based DNA-damaging chemotherapy is standard-of-care for most patients with lung cancer but outcomes remain poor. This has been attributed, in part, to the highly effective repair network known as the DNA-damage response (DDR). ATR kinase is a critical regulator of this pathway, and its inhi...
Autores principales: | Hall, Amy B., Newsome, Dave, Wang, Yuxin, Boucher, Diane M., Eustace, Brenda, Gu, Yong, Hare, Brian, Johnson, Mac A., Milton, Sean, Murphy, Cheryl E., Takemoto, Darin, Tolman, Crystal, Wood, Mark, Charlton, Peter, Charrier, Jean-Damien, Furey, Brinley, Golec, Julian, Reaper, Philip M., Pollard, John R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170644/ https://www.ncbi.nlm.nih.gov/pubmed/25010037 |
Ejemplares similares
-
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
por: Yap, Timothy A., et al.
Publicado: (2020) -
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours
por: Middleton, Mark R., et al.
Publicado: (2021) -
Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
por: Pires, I M, et al.
Publicado: (2012) -
Looking back over the 1 970s
Publicado: (1979) -
Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
por: Sanjiv, Kumar, et al.
Publicado: (2015)